The Latest Breaking News from ELAN

Despite the company’s higher-than-industry average profitability and solid earnings growth prospects, the shares of Elanco Animal Health are trading way below their 52-week price high. So, is it wise to buy the dip in the stock? Read on to learn our view.

Elanco Animal Health Inc (NYSE:ELAN) has reported a Q1 EPS of $0.36, lower than the $0.37 reported a year ago, surpassing analysts' view of $0.35. Revenue was $1.225 billion, a decrease of 1% YY, slightly above the consensus of $1.22 billion. Pet Health's revenue decreased by 1% and was up 2% when excluding…

Elanco Animal Health (NYSE:ELAN) will host a conference call at 08:00 AM ET on May 9, 2022, to discuss Q1 2022 earnings results. How to Attend Elanco Animal Health (ELAN) Conference Call Follow this link to access the live webcast.

Elanco Animal Health Incorporated (NYSE:ELAN) and Ginkgo Bioworks Holdings Inc (NYSE:DNA) have launched BiomEdit, a microbiome innovation company. BiomEdit will discover, develop and introduce novel probiotics, bioactive molecules, engineered microbial medicines, and microbial monitoring services for animal health. In October last year, Elanco announced its intention to carve out its microbiome platform and pipeline under the leadership…